β1-adrenergic receptor blockade attenuates angiotensin II-mediated catecholamine release into the cardiac interstitium in mitral regurgitation

Circulation

Volumn 108, Issue 2, 2003, Pages 225-230

  Tallaj, José ^a   Wei, Chih Chang ^a   Hankes, Gerald H ^a   Holland, Merrilee ^a   Rynders, Patricia ^a   Dillon, A Ray ^a   Ardell, Jeffrey L ^b   Armour, J Andrew ^c   Lucchesi, Pamela A ^a   Dell'Italia, Louis J ^a,d  

^a AUBURN UNIVERSITY   (United States)

^b EAST TENNESSEE STATE UNIVERSITY   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d University of Alabama at Birmingham   (United States)

Author keywords

Angiotensin; Heart failure; Nervous system, autonomic; Receptors, adrenergic, beta; Renin

Indexed keywords

ADRENALIN; ANGIOTENSIN; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE; METOPROLOL SUCCINATE; NORADRENALIN; UNCLASSIFIED DRUG; ANGIOTENSIN II; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COLLAGEN; DRUG DERIVATIVE; METOPROLOL;

ANGIOTENSIN BLOOD LEVEL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CATECHOLAMINE RELEASE; CONTROLLED STUDY; DOG; ENZYME ACTIVITY; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; INTERSTITIAL FLUID; MITRAL VALVE REGURGITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYMPATHETIC NERVE CELL; ANIMAL; DISEASE MODEL; DRUG ADMINISTRATION ROUTE; DRUG ANTAGONISM; DRUG EFFECT; EXTRACELLULAR SPACE; FEMALE; HEART; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEMODYNAMICS; INNERVATION; MALE; METABOLISM; NERVE CELL; PATHOPHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II; ANIMALS; CATECHOLAMINES; COLLAGEN; DISEASE MODELS, ANIMAL; DOGS; DRUG ADMINISTRATION ROUTES; EPINEPHRINE; EXTRACELLULAR SPACE; FEMALE; HEART; HEMODYNAMIC PROCESSES; MALE; METOPROLOL; MITRAL VALVE INSUFFICIENCY; MYOCARDIUM; NEURONS; NOREPINEPHRINE; RECEPTORS, ADRENERGIC, BETA-1; VENTRICULAR FUNCTION, LEFT;

EID: 0038447264     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000079226.48637.5A     Document Type: Article

References (20)

1. Mann DL, Kent RL, Parsons B, et al. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85:790-804.
2. Brasch H, Sieroslawski L, Dominiak P. Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors. Hypertension. 1993;22:699-704.
3. Farrell DM, Wei CC, Tallaj J, et al. Angiotensin II modulates catecholamine release into the interstitial fluid of the canine myocardium in vivo. Am J Physiol. 2001;281:H813-H822.
4. Brink M, de Gasparo M, Rogg H, et al. Localization of angiotensin II receptor subtypes in the rabbit heart. J Mol Cell Cardiol. 1995;27: 459-470.
5. Henegar JR, Brower GL, Kabour A, et al. Catecholamine response to chronic Ang II infusion and its role in myocyte and coronary vascular damage. Am J Physiol. 1995;269(Heart Circ Physiol. 38):H1564-H1569.
6. Henegar JR, Schwartz DD, Janicki JS. Ang II-related myocardial damage: role of cardiac sympathetic catecholamines and β-receptor regulation. Am J Physiol. 1998;275(Heart Circ Physiol. 44):H534-H541.
7. Dell'Italia LJ, Meng QC, Balcells E, et al. Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation. Am J Physiol. 1995;269:H2065-H2073.
8. Dell'Italia LJ, Balcells E, Meng QC, et al. Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs. Am J Physiol. 1997;273:H961-H970.
9. Perry GJ, Wei CC, Su X, et al. Afterload reduction and blockade of the tissue renin angiotensin system does not improve left ventricular and cardiomyocyte remodeling in chronic mitral regurgitation. J Am Coll Cardiol. 2002;39:1374-1379.
10. Tsutsui H, Spinale FG, Nagatsu M, et al. Effects of chronic β-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. J Clin Invest. 1994;93:2639-2648.
11. Dell'Italia LJ, Meng QC, Balcells E, et al. Compartmentalization of angiotensin II generation in the dog heart: evidence for independent mechanisms in intravascular and interstitial spaces. J Clin Invest. 1997; 100:253-258.
12. Perronnet F, Boudreau G, de Champlain J, et al. Effect of increases in myocardial epinephrine content on epinephrine release from the dog heart. Can J Physiol Pharmacol. 1993;71:884-888.
13. Heeneman S, Smits JFM, Leenders PJA, et al. Effects of angiotensin II on cardiac function and peripheral vascular structure during compensated heart failure in the rat. Arterioscler Thromb Vasc Biol. 1997;17: 1985-1994.
14. Regitz-Zagrosek V, Friedel N, Heymann A, et al. Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts. Circulation. 1995;91:1461-1471.
15. Saris JJ, Derkx FHM, Lamers JMJ, et al. Cardiomyocytes bind and activate native human prorenin: role of soluble mannose 6-phospahte receptors. Hypertension. 2001;37:710-715.
16. Zisman LS, Asano K, Dutcher DL, et al. Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart. Circulation. 1998;98:1735-1741.
17. Mann DL, Spinale FG. Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. Circulation. 1998;98: 1699-1702.
18. Stewart JA, Wei C-C, Lucchesi PA, et al. Differential activation of ACE and chymase during early and late phases of left ventricular remodeling in response to the volume overload of mitral regurgitation. Circulation. 2000;102(suppl II):11-131. Abstract.
19. Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol. 2001;280:C53-C60.
20. Senzaki H, Paolocci N, Gluzband YA, et al. β-Blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction. Circ Res. 2000;86:807-815.